Krystal Biotech stock gained 3.90 percent on October 5

Published on 10/06/2026 at 09:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Krystal Biotech stock closed at USD 334.85 on October 5 after revenue reached USD 119.2 million in Q2. Analysts see a USD 365.40 average target.

KRYS, US5011471027, Illustration mit AI erstellt.

Krystal Biotech (ISIN US5011471027) closed at USD 334.85 on Nasdaq on October 5, 2026, gaining 3.90 percent on the session. The move followed a second quarter in which revenue rose 24.14 percent year over year to USD 119.2 million, according to Zacks.

Vyjuvek drives second quarter growth

Krystal generated USD 119.2 million from Vyjuvek in Q2 2026, up from USD 96.0 million in the year-earlier quarter. Gross margin reached 95 percent, while diluted EPS came in at USD 1.79 against a USD 1.70 consensus estimate, giving the company a USD 0.09 earnings beat, Zacks reported on September 2, 2026.

Net income was USD 54.77 million, compared with USD 38.33 million in Q2 2025, according to Markets Insider on September 24, 2026. The result gives investors a clear comparison: revenue expanded by USD 23.18 million while net income increased by USD 16.44 million year over year.

Analysts see room above USD 365

MarketBeat reported on September 18, 2026, that 13 research firms held a Moderate Buy consensus, including 10 Buy ratings, one Strong Buy and two Holds. The average 12-month price target was USD 365.40, while recent targets reached USD 474.00.

Goldman Sachs resumed coverage with a Buy rating and a USD 441.00 target on September 24, 2026, while Bank of America maintained Buy with a USD 400.00 target, Markets Insider reported. Against the October 5 close, the consensus target stood 9.11 percent above the stock price.

Pipeline breadth remains the valuation test

VYJUVEK generated the current commercial base, but the valuation discussion extends beyond one product. Yahoo Finance reported on October 5, 2026, that Krystal had more than 730 U.S. reimbursement approvals and two other programs in registrational studies. The same report put the forward earnings multiple at 46.95, highlighting the market's reliance on continued commercial execution and pipeline progress.

Krystal Biotech stock stays below its yearly high

Krystal Biotech stock closed at USD 334.85 on Nasdaq on October 5, 2026. The session range was USD 321.37 to USD 339.69, the 52-week range was USD 179.19 to USD 382.54, and market capitalization was USD 9.9 billion.